(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a ...
Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...
Entasis’ Nuzolvence and GSK’s Blujepa are the first antibiotic approvals in gonorrhoea in over 30 years in the US.
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
Milestone Pharmaceuticals won FDA approval for a new nasal-spray medicine to treat episodes of paroxysmal supraventricular ...
Zacks Investment Research on MSN
GSK's Nucala for COPD and Depemokimab for asthma get CHMP nod in EU
GSK plc GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...
GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease: London, UK Monday, December 15, 2025, 16:00 Hrs [IST] GSK plc announced that ...
Riad Mishlawi is stepping down from the top role by ‘mutual agreement’ with the firm’s board of directors, it told investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback